- Delivering Pan India
Filgrastim 300mcg/0.5mL Pre-filled Syringe — G-CSF
| Composition | Filgrastim 300 mcg/0.5 mL |
|---|---|
| Manufacturer | Axiommax Oncology Pvt Ltd |
| Country | India |
| Pack size | 1 pre-filled syringe (0.5 mL) |
| Storage | 2°C to 8°C in original carton, protect from light (reference label) |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Axokine® (Filgrastim) — Granulocyte Colony-Stimulating Factor: A Sourcing Guide for Hospitals and Oncology Pharmacies
Axokine® is a brand of filgrastim injection, 300 mcg in a 0.5 mL pre-filled syringe, marketed by Axiommax Oncology. Filgrastim is a leukocyte growth factor (granulocyte colony-stimulating factor, G-CSF). According to the approved US prescribing information for filgrastim (Neupogen®, the reference product), it is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs, and for several other neutropenia-related uses described in the label. The decision to prescribe filgrastim, including timing and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Axokine (Filgrastim) to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Axokine contains filgrastim, a recombinant form of human granulocyte colony-stimulating factor. The prescribing information describes endogenous G-CSF as a lineage-specific colony-stimulating factor that regulates the production of neutrophils in the bone marrow.
How it works, according to the label: Colony-stimulating factors are glycoproteins that act on blood-forming cells by binding to specific cell surface receptors, stimulating proliferation, differentiation commitment and some end-cell functional activation. The label states that G-CSF has minimal direct effects on blood cell types other than the neutrophil lineage.
The indications below summarise the US prescribing information for filgrastim (reference brand Neupogen, DailyMed). Indications in India are defined by the Indian regulator and the product’s own label, and the full US label lists further uses.
The study below is summarised as described in the prescribing information and its publication. It is cited for information about the evidence behind the label and is not a recommendation for any patient.
| Brand | Presentation | Strength | Administration |
|---|---|---|---|
| Axokine® (Axiommax Oncology) | Pre-filled syringe | Filgrastim 300 mcg per 0.5 mL | Injection for I.V. or S.C. use, as printed on the pack |
Dosing for filgrastim is described in the prescribing information as weight-based and differs by use. It must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, oncology and haematology department buyers, and pharmacies that stock supportive-care injections for cancer centres. Filgrastim is prescribed and monitored by a qualified physician, as described in the prescribing information.
The US prescribing information for filgrastim lists warnings including fatal splenic rupture, acute respiratory distress syndrome, serious allergic reactions including anaphylaxis, fatal sickle cell crises, glomerulonephritis, myelodysplastic syndrome and acute myeloid leukemia in patients with breast and lung cancer, thrombocytopenia, and large and medium vessel arteritis. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
The US label for the reference product states that filgrastim should be stored refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light and physical damage, should not be shaken, and should be protected from freezing. Follow the storage instructions printed on the Axokine pack.
Axokine is marketed by Axiommax Oncology Pvt Ltd, India. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we supply Axokine with pack and batch details on request. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Axokine available in India?
Axokine is an Indian brand marketed by Axiommax Oncology. A.K. Pharma supplies it to hospitals and pharmacies; contact us for current availability.
What does Axokine contain?
Filgrastim 300 mcg per 0.5 mL in a pre-filled syringe.
Can I order a single syringe?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Axokine be stored?
The reference US label states 2°C to 8°C in the original carton, protected from light. Follow the pack instructions.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
